JP2016522259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522259A5 JP2016522259A5 JP2016521549A JP2016521549A JP2016522259A5 JP 2016522259 A5 JP2016522259 A5 JP 2016522259A5 JP 2016521549 A JP2016521549 A JP 2016521549A JP 2016521549 A JP2016521549 A JP 2016521549A JP 2016522259 A5 JP2016522259 A5 JP 2016522259A5
- Authority
- JP
- Japan
- Prior art keywords
- oligopeptide
- seq
- amino acid
- peptide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 90
- 150000001413 amino acids Chemical group 0.000 claims description 56
- 108010038807 Oligopeptides Proteins 0.000 claims description 43
- 102000015636 Oligopeptides Human genes 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 230000002163 immunogen Effects 0.000 claims description 13
- 231100000617 superantigen Toxicity 0.000 claims description 10
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 102000028861 calmodulin binding Human genes 0.000 claims description 4
- 108091000084 calmodulin binding Proteins 0.000 claims description 4
- 231100000655 enterotoxin Toxicity 0.000 claims description 4
- 239000005090 green fluorescent protein Substances 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 2
- 108050001427 Avidin/streptavidin Proteins 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 2
- 241001195348 Nusa Species 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 102000044159 Ubiquitin Human genes 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 108010090623 galactose binding protein Proteins 0.000 claims description 2
- 102000021529 galactose binding proteins Human genes 0.000 claims description 2
- 230000005745 host immune response Effects 0.000 claims description 2
- 101150066555 lacZ gene Proteins 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 101150044170 trpE gene Proteins 0.000 claims description 2
- 101001023095 Anemonia sulcata Delta-actitoxin-Avd1a Proteins 0.000 claims 1
- 101000641989 Araneus ventricosus Kunitz-type U1-aranetoxin-Av1a Proteins 0.000 claims 1
- 101001028691 Carybdea rastonii Toxin CrTX-A Proteins 0.000 claims 1
- 101000685083 Centruroides infamatus Beta-toxin Cii1 Proteins 0.000 claims 1
- 101000685085 Centruroides noxius Toxin Cn1 Proteins 0.000 claims 1
- 101001028688 Chironex fleckeri Toxin CfTX-1 Proteins 0.000 claims 1
- 101000644407 Cyriopagopus schmidti U6-theraphotoxin-Hs1a Proteins 0.000 claims 1
- 101000679608 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) Cysteine rich necrotrophic effector Tox1 Proteins 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 19
- 229920003259 poly(silylenemethylene) Polymers 0.000 description 12
- -1 X 15 Chemical compound 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 5
- 108010014603 Leukocidins Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 101710092462 Alpha-hemolysin Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 101001047889 Staphylococcus aureus Delta-hemolysin Proteins 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010044250 Toxic shock syndrome staphylococcal Diseases 0.000 description 1
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- OPGTXAUDXWCGFI-UHFFFAOYSA-N [1-[[6-[[3-(3-dodecanoyloxytetradecanoylamino)-6-(hydroxymethyl)-5-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate Chemical compound OC1C(O)C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)OC1COC1C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C(OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(OP(O)(O)=O)C(CO)O1 OPGTXAUDXWCGFI-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000017756 staphylococcal toxic-shock syndrome Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836959P | 2013-06-19 | 2013-06-19 | |
| US61/836,959 | 2013-06-19 | ||
| PCT/US2014/042999 WO2014205111A1 (en) | 2013-06-19 | 2014-06-18 | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522259A JP2016522259A (ja) | 2016-07-28 |
| JP2016522259A5 true JP2016522259A5 (enExample) | 2017-07-27 |
| JP6632974B2 JP6632974B2 (ja) | 2020-01-22 |
Family
ID=52105236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521549A Active JP6632974B2 (ja) | 2013-06-19 | 2014-06-18 | フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9815872B2 (enExample) |
| EP (1) | EP3010535B1 (enExample) |
| JP (1) | JP6632974B2 (enExample) |
| CA (1) | CA2916231C (enExample) |
| DK (1) | DK3010535T3 (enExample) |
| PT (1) | PT3010535T (enExample) |
| WO (1) | WO2014205111A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2916231C (en) | 2013-06-19 | 2024-02-06 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
| WO2018037408A1 (en) * | 2016-08-22 | 2018-03-01 | Technion Research & Development Foundation Limited | Antimicrobial peptides and uses thereof |
| EP3532618A4 (en) * | 2016-10-27 | 2020-05-20 | MedImmune, LLC | SIGNAL POLYPEPTIDES FOR IMPROVED PROTEIN SECRETION |
| CN107224575B (zh) * | 2017-03-06 | 2018-11-09 | 浙江海隆生物科技有限公司 | 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用 |
| MX2020001046A (es) | 2017-07-27 | 2020-08-06 | Integrated Biotherapeutic Vaccines Inc | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. |
| CN115427433A (zh) | 2020-12-18 | 2022-12-02 | 生物医学研究及生物制品公司 | 保护性葡萄球菌外毒素疫苗 |
| US12370235B2 (en) | 2021-03-04 | 2025-07-29 | University Of Saskatchewan | Synthetic, non-natural antimicrobial peptides inspired by Staphylococcus auricularis delta toxin |
| GR1010289B (el) * | 2021-04-27 | 2022-08-29 | Integrated Biotherapeutic Vaccines, Inc., | Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων |
| CN113234125B (zh) * | 2021-05-10 | 2022-12-06 | 华东理工大学 | 自组装多肽、多肽水凝胶及其制备方法和用途 |
| WO2023227563A1 (en) | 2022-05-23 | 2023-11-30 | Biomedizinische Forschung & Bio-Produkte AG | Protective staphylococcal exotoxin vaccine |
| WO2023247747A1 (en) | 2022-06-23 | 2023-12-28 | Biomedizinische Forschung & Bio-Produkte AG | Protective staphylococcal exotoxin vaccine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6593114B1 (en) * | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| US7087235B2 (en) * | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| AU761021B2 (en) * | 1998-07-10 | 2003-05-29 | U.S. Medical Research Institute Of Infectious Diseases Department Of The Army | Vaccine against staphylococcus intoxication |
| GB0118155D0 (en) | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| NZ561879A (en) * | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| US20050008633A1 (en) | 2003-05-19 | 2005-01-13 | Advanced Inhalation Research Inc. | Chemical and physical modulators of bioavailability of inhaled compositions |
| US7754225B2 (en) | 2006-07-20 | 2010-07-13 | Glaxosmithkline Biologicals S.A. | Method of protecting against staphylococcal infection |
| WO2008154101A1 (en) * | 2007-06-06 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus |
| KR20100072228A (ko) * | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| AU2012214677B2 (en) | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| CN103561762A (zh) * | 2011-03-16 | 2014-02-05 | 明尼苏达大学董事会 | 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法 |
| CA2857666C (en) | 2011-12-02 | 2020-08-11 | Integrated Biotherapeutics, Inc. | Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides |
| CA2916231C (en) | 2013-06-19 | 2024-02-06 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
-
2014
- 2014-06-18 CA CA2916231A patent/CA2916231C/en active Active
- 2014-06-18 EP EP14813512.2A patent/EP3010535B1/en active Active
- 2014-06-18 WO PCT/US2014/042999 patent/WO2014205111A1/en not_active Ceased
- 2014-06-18 DK DK14813512.2T patent/DK3010535T3/da active
- 2014-06-18 JP JP2016521549A patent/JP6632974B2/ja active Active
- 2014-06-18 US US14/899,993 patent/US9815872B2/en active Active
- 2014-06-18 PT PT148135122T patent/PT3010535T/pt unknown
-
2017
- 2017-11-13 US US15/810,419 patent/US10174085B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Confer et al. | Mannheimia haemolytica in bovine respiratory disease: immunogens, potential immunogens, and vaccines | |
| JP2014507142A5 (enExample) | ||
| Kuipers et al. | Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization | |
| EP3321287B1 (en) | Fusion proteins & combination vaccines | |
| JP2011512152A (ja) | 改善された溶解度を有するＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原 | |
| AU2019404924B2 (en) | O-linked glycosylation recognition motifs | |
| JP2021528059A (ja) | グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用 | |
| JP2015505831A5 (enExample) | ||
| US8007806B2 (en) | Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide | |
| CN103068838A (zh) | 基于重组蛋白的抗链球菌感染疫苗 | |
| CN109456393B (zh) | 肺炎链球菌蛋白在抗肺炎链球菌感染中的应用 | |
| de Oliveira et al. | A novel chimeric protein composed of recombinant Mycoplasma hyopneumoniae antigens as a vaccine candidate evaluated in mice | |
| KR101130884B1 (ko) | 패혈증 비브리오균의 플라젤린과 병원체의 항원 단백질을 융합시켜 제조한 재조합 융합 단백질 및 이를 유효성분으로 포함하는 점막 투여용 백신 | |
| JP2023503058A (ja) | ヘモフィルス・パラスイスに対する新規ワクチン | |
| US12280097B2 (en) | Optimized cell-free synthesis of invasion plasmid antigen B and related compositions and methods of use | |
| Wu et al. | Engineering detoxified pneumococcal pneumolysin derivative ΔA146PLY for self-biomineralization of calcium phosphate: Assessment of their protective efficacy in murine infection models | |
| TWI683668B (zh) | 用於免疫作用中有效抗體生産的新穎蛋白質結構 | |
| CN113631186B (zh) | 肺炎球菌表面蛋白 | |
| Chen et al. | Designing, expression and immunological characterization of a chimeric protein of Mycoplasma pneumoniae | |
| JP2020537488A5 (enExample) | ||
| Liu et al. | Be aware of immunogenic but not protective antigens: the Actinobacillus pleuropneumoniae PalA as an example | |
| JP6964623B2 (ja) | Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用 | |
| TWI638827B (zh) | 交叉保護性重組抗原及含彼之動物疫苗組成物 | |
| Vasquez et al. | Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant | |
| TWI635869B (zh) | 生物型佐劑及含彼之動物疫苗組成物 |